iGene Laboratory, a leading Singapore molecular diagnostics company for women’s and reproductive health is pleased to announce that it has been awarded the College of American Pathologist (CAP) accreditation for the Non-Invasive Prenatal Test (NIPT).
CAP is the world’s largest association composed exclusively of board-certified pathologists and is the global leader in laboratory quality assurance. This recognition adds to the certification previously received from Singapore’s Ministry of Health.
“The CAP accreditation represents the highest benchmark for lab testing in the industry and is based on an entire spectrum of laboratory test disciplines with the most scientifically rigorous customised checklist requirements. iGene is proud to be among a small group of Next Generation Sequencing (NGS)-specialised diagnostic laboratories to receive this accreditation, reaffirming our commitment to achieve the highest standards of excellence to positively impact patient care in Singapore and the region,” said Dr Chang Chia Pin, Vice President, iGene Laboratory.
iGene Laboratory set up a state-of-the art NGS Laboratory in Singapore in 2015, and currently provides testing services to clinics and hospitals in Singapore and the region, including Malaysia, Indonesia, Cambodia and Myanmar.
iGene Laboratory is a wholly owned subsidiary of INEX Innovations Exchange and is currently collaborating with world class institutions such as the National University of Singapore and A*Star to develop new technologies in women’s and reproductive health.
About iGene Laboratory Pte Ltd
Established in 2014, iGene Laboratory Pte Ltd is a wholly owned subsidiary of INEX Innovations Exchange Pte Ltd. iGene Laboratory offers cutting edge tests rooted in advanced technological platforms such as next generation sequencing to efficiently garner the most precise data and analyses. In turn, patients and physicians are equipped to make the most informed decision for better medical outcomes.
iGene® is a revolutionary non-invasive prenatal blood test that can detect fetal chromosomal abnormalities such as Down Syndrome with more than 99% accuracy. The test has drastically changed the course of prenatal screening because it offers expectant mothers accurate results without the risk of miscarriage. It is anticipated that the use of iGene® as a prenatal screening tool will reduce the rate of invasive procedures such as amniocenteses by as much as 95%. For more information, visit www.igeneprenataltest.com
Singapore’s iGene Laboratory Receives CAP Accreditation for NIPT
Established in 2006, INEX is a Singapore-based women’s health diagnostic company founded by professors and clinicians, dedicated to developing innovative and disruptive technologies for the advancement of women’s and reproductive health. For more information, visit www.inex.sg